Dr. Abraham Schneider: Leading Research Into the Future of Oral Health

With funding from the National Institute for Dental and Craniofacial Research, Dr. Abraham Schneider and his research team are exploring metformin’s key cellular and molecular factors that may support a pro-regenerative tissue microenvironment.

“When cells are treated with concentrations of metformin that are compatible with those taken orally by diabetics, we found it induces the expression of genes involved in bone formation and dentin,” Dr. Schneider says. “This is an exciting discovery that may offer a cost-effective drug repurposing strategy for regenerating mineralized tissues that are damaged by trauma or disease.”

Image